PET Imaging Agent for Non-Small Cell Lung Cancer

This trial explores a new PET imaging agent to assess treatment effectiveness in individuals with stage IV non-small cell lung cancer. The agent employs a specialized scan to determine tumor growth, aiding doctors in making informed treatment decisions. It targets patients already receiving pembrolizumab and whose tumors are treatable with precise radiation known as SBRT. Those with stage IV non-small cell lung cancer undergoing pembrolizumab treatment might find this trial suitable. As a Phase 1 trial, the research focuses on understanding the treatment's effects in people, providing participants the opportunity to benefit from this innovative approach.

The trial does not specify if you need to stop taking your current medications, but you must continue taking pembrolizumab. You should not use immunosuppressive medications within 14 days before the study, except for certain low-dose steroids and specific premedications.

Research has shown that pembrolizumab, a key component of the new PET imaging agent under study, is generally safe for patients with advanced non-small cell lung cancer (NSCLC). Several studies indicate that pembrolizumab, whether used alone or with chemotherapy, is safer than chemotherapy alone. It has effectively helped patients live longer and slowed cancer growth.

Specific safety information for the new PET imaging agent, 64Cu-DOTA-pembrolizumab, is not yet available, but the use of pembrolizumab in this combination appears promising. This trial is in its early stages, and researchers are beginning to assess the safety of the new imaging agent. This phase is crucial for identifying any side effects and understanding the body's response.

Researchers are excited about the investigational approach in this trial because it combines pembrolizumab, a standard immunotherapy, with a novel PET imaging agent, 64Cu-DOTA-pembrolizumab. This unique combination allows for real-time imaging of how the drug interacts with non-small cell lung cancer cells, potentially offering more precise and personalized treatment plans. Unlike traditional therapies that rely solely on treatment cycles, this method could help doctors see how well the drug is working much earlier. This innovative use of imaging could lead to quicker adjustments in treatment, making it a promising advancement in cancer care.

Studies have shown that pembrolizumab effectively treats non-small cell lung cancer (NSCLC). Patients receiving pembrolizumab lived longer without cancer progression, averaging 10.3 months compared to 6.0 months for those on chemotherapy. More patients survived at 36 months, with survival rates of 57.9% after one year, 53.5% after two years, and 42.8% after three years. Pembrolizumab was effective for 45.2% of patients with high levels of PD-L1, a protein on tumor cells. In this trial, participants will receive pembrolizumab along with a new PET imaging agent, 64Cu-DOTA-pembrolizumab, which helps doctors identify tumors still growing during treatment, potentially improving treatment response assessment.¹²⁵⁶⁷